39740-30-2

39740-30-2 structure

Name: Etilevodopa hydrochloride
Chemical Name: (S)-3,4-dihydroxyphenylalanine ethyl ester hydrochloride
CAS Number: 39740-30-2
Molecular Formula: C₁₁H₁₆ClNO₄
Molecular Weight: 261.70200
Catalog: Signaling Pathways GPCR/G Protein Dopamine Receptor
Create Date: 2018-06-22 10:16:18
Modify Date: 2024-01-09 10:45:14
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester prodrug of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable prodrug as it facilitates CNS penetration and delivers dopamine[1][2][3].

Name	(S)-3,4-dihydroxyphenylalanine ethyl ester hydrochloride
Synonyms	L-DOPA Ethyl Ester Hydrochloride

Description	Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester prodrug of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable prodrug as it facilitates CNS penetration and delivers dopamine[1][2][3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
In Vitro	Etilevodopa (L-Dopa ethyl ester) hydrochloride passes unchanged through the stomach to the duodenum, where it is rapidly hydrolyzed by local esterases to Levodopa and ethanol, and is subsequently absorbed into the blood stream as Levodopa[1]. Compared with standard Levodopa, Etilevodopa hydrochloride has greater solubility in the stomach, faster passage to the small intestine, and a shortened time to maximum Levodopa concentration[2].
References	[1]. Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. [2]. Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. [3]. Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23(1). pii: E40.

Molecular Formula	C₁₁H₁₆ClNO₄
Molecular Weight	261.70200
Exact Mass	261.07700
PSA	92.78000
LogP	2.03300

39740-30-2	1406-14-0
6138-79-0	127228-87-9
143851-98-3	929-73-7
65546-09-0	1135280-78-2
56-99-5	1406-02-6
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
1108725-35-4	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1